Should I buy Haemonetics (HAE) stock or is it too late?
⭐ The most reliable of them, either direction: Mizuho — 64% of its targets hit on this sector (70 calls tested). It aims for $90 (-14 %), call made on July 16, 2026, maturing on July 16, 2027 (43 d ago).
Firm-by-firm track record on Haemonetics
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Mizuho | 60 % | +12.4 % | 5 | $90 -14% |
| JMP Securities | 55 % | +10.8 % | 11 | $100 -5% |
| Jefferies | 60 % | +4.2 % | 10 | $85 -19% |
| Barrington Research | 42 % | -1.0 % | 24 | $118 +12% |
| Raymond James | 42 % | -6.0 % | 24 | $78 -26% |
| Needham | 27 % | -10.9 % | 11 | $78 -26% |
| Morgan Stanley | 56 % | -6.0 % | 9 | — |
✅ Reasons to believe
- 71% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
⚠️ Reasons to hesitate
- Even the most reliable firm on HAE, Mizuho (60% hit rate, 5 scored calls), only targets $90 (call made on July 15, 2026, maturing on July 15, 2027) (-14%) in its most recent call, and $90 (call made on December 17, 2025, maturing on December 17, 2026) (-14%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 7 ratings, 2 are neutral.
- Limited upside: the median target is only -12% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on HAE
Median target $92 (-12%) · 7 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Haemonetics now?
We won't decide for you. The facts: 71% of analysts rate it a buy, median target $92 (-12%), and Mizuho (most reliable on HAE, 60%) targets $90. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Haemonetics?
The stated upside is small: the median target ($92) sits just -12% from the price ($105) (most reliable on HAE: Mizuho, 60%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Haemonetics still worth investing in?
It depends on the gap between the price ($105) and its estimated value: analysts target $92 on median (-12%), with 71% buys (most reliable on HAE: Mizuho, 60%). Cross-check with their real reliability on HAE and the cautions above. Information, not advice.
What's the main risk in buying HAE?
Even the most reliable firm on HAE, Mizuho (60% hit rate, 5 scored calls), only targets $90 (call made on July 15, 2026, maturing on July 15, 2027) (-14%) in its most recent call, and $90 (call made on December 17, 2025, maturing on December 17, 2026) (-14%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Haemonetics profile (consensus, analyst reliability, price target, performance).